Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Prevail Therapeutics Inc.
Headquarters: New York, NY, United States of America
Website: N/A
Year Founded: 2017
Status: Acquired
BioCentury | Mar 4, 2025
Management Tracks
Head of R&D Robert Lenz to leave Neumora
Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more
BioCentury | Apr 10, 2024
Management Tracks
PureTech’s Zohar takes CEO role at new portfolio company targeting CNS
Plus: AskBio hires former Prevail CSO, and updates from Illumina, Xencor, Adcentrx, enGene and more
BioCentury | Jan 19, 2023
Management Tracks
Janssen’s Linda Wu to head development at Jiangsu Yahong
Plus: new CEO at Atriva, and updates from Hinge Bio, Capsida, Sensorium, CXL and Patient Square
BioCentury | Oct 18, 2022
Deals
Lilly buying otology company Akouos to add another gene therapy pipeline
As biotech nears first-in-human study for genetic hearing loss, pharma deepens commitment to modality via structured deal
BioCentury | Feb 23, 2022
Product Development
Lilly aims for technology synergies with unified genetic medicines group
The Lilly Institute for Genetic Medicine brings DNA, RNA therapies under one group — and it’s seeking delivery deals
BioCentury | Dec 17, 2021
Finance
Omega to stress company creation with largest fund
Omega Funds closes oversubscribed seventh fund at $650M
BioCentury | Sep 30, 2021
Product Development
Gaucher disease pipeline: Data Byte
Three clinical and 11 preclinical candidates move beyond traditional enzyme replacement, aim for wider range of patients
BioCentury | Jan 27, 2021
Finance
Pontifax’s largest-ever fund, at $404M, will help firm maintain stakes in growth-stage portfolio companies
Israeli VC will continue to hunt for ‘diamonds in the rough’
BioCentury | Dec 22, 2020
Deals
Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more
Cytokinetics regains European rights from Servier to heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier. The deal
BioCentury | Dec 15, 2020
Deals
Prevail acquisition affords Lilly an ‘entry point’ in gene therapy, with more deals likely to follow
In Prevail, Lilly found an M&A target with expertise in one of its core areas — neuroscience — that can also be a building block around which it expects to amass a gene therapy
Items per page:
1 - 10 of 25